; (ii) activities to develop and scale up new technologies and approaches, including those identified by public-private partnerships, for research and innovation; (iii) coordination with United States agencies, foreign governments, nongovernmental organizations, and international organizations; (iv) methods used to leverage new financial and other public and private resources in innovative ways; and (v) best practices identified by the executive branch. (E) Reporting on grants, contracts, and cooperative agreements awarded, including— (i) a comprehensive list of USAID grants, contracts, and cooperative agreements awarded in implementation of the strategy established under subsection (d)(1); and (ii) a description of— (I) the targets for coverage of interventions or services and the baseline against which they are measured and the status of progress in meeting the targets; or (II) in the case of exceptional circumstances where USAID determines that inclusion of targets or baseline measurements is not reasonable or practicable, an explanation of how the impact of the grant, contract, agreement, or resulting program is being measured. (F) Reporting on the innovative public-private financing tools, including an analysis of the feasibility and potential effectiveness of new financing tools that could be used to fund efforts to end preventable child and maternal deaths globally. (h) Authorization of appropriations (1) Authorization For each of fiscal years 2020 and 2021, there is authorized to be appropriated to the Secretary of State and the Administrator of the United States Agency for International Development to carry out this section— (A) $545,000,000 for bilateral maternal and child health; (B) $290,000,000 for Gavi, the Vaccine Alliance